Summation Health Ventures

The firm deploys capital across the full venture lifecycle, from early-stage startups through expansion and late-stage growth rounds. This stage-agnostic approach allows it to support companies from initial clinical validation through commercialization and scaling.

Yes. Summation Health Ventures is a dedicated healthcare-technology investor. Its mandate concentrates on companies where clinical validation, regulatory approval, and reimbursement pathways are central to the business model, distinguishing it from generalist technology funds.

Specific sourcing channels are not publicly detailed. Given the firm's healthcare focus, origination likely depends on domain-expert networks within health systems, clinical research institutions, and payer organizations, though the firm does not publicly describe its deal-flow architecture.

The firm does not publicly name its managing principals or investment committee members. This low public profile suggests a tight partnership structure, but individual decision-makers are not listed in available public records.

The firm is categorized as a private equity firm but operates with a venture capital mandate across early and late stages. This hybrid posture reflects an investment philosophy suited to healthcare, where returns often depend on long-duration regulatory catalysts rather than rapid growth alone.